Attenuation of Atherosclerosis by 3,4-Dihydroxy-Hydrocinnamic Acid in Rabbits by Partial Inhibition of ACAT

Mi-Ran Lee1, Jae-Hoon Choi2, Young Yang3, Ki Sook Oh3, Tae-Sook Jeong4, Chul-Ho Lee4, Goo Taeg Oh5

1Department of Biomedical Laboratory Science, Jungwon University, Goesan 28024, Korea
2Department of Life Science, College of Natural Sciences, Research Institute of Natural Sciences, Hanyang University, Seoul 04763, Korea
3Research Center for Women’s Disease, Department of Life Science, Sookmyung Women’s University, Seoul 04310, Korea
4Industrial Bio-materials Research Center, Korea Research Institute of Bioscience and Biotechnology (KRIBB), Daejeon 34141, Korea
5Department of Life Sciences, Ewha Womans University, Seoul 03760, Korea

Polyphenols have been reported to have beneficial effects on cardiovascular disease. A polyphenolic compound, 3,4-dihydroxy-hydrocinnamic acid (3,4-DHHCA), has been shown to have antioxidative and antitumorigenic activities. However, the effect of 3,4-DHHCA on atherosclerosis is still unknown. Herein, we investigated the effects of 3,4-DHHCA on atherosclerosis in New Zealand White rabbits. Broad and fused fatty streak lesions were found in rabbits fed with high-cholesterol diet for 8 weeks. Administration of 3,4-DHHCA reduced atherosclerotic lesion formation and lesional accumulation of macrophage in rabbits fed with cholesterol diet without systemic or local toxicity. Hepatic acyl-coenzyme A: cholesterol acyltransferase (ACAT) activity was decreased after treatment with 3,4-DHHCA by 22% in cholesterol diet-fed rabbits compared with the control group. These results indicate that 3,4-DHHCA had antiatherogenic effects in rabbits, possibly by partial inhibition of ACAT.

Key words: Atherosclerosis, 3,4-dihydroxy-hydrocinnamic acid, Animal models, Acyl-CoA:cholesterol acyltransferase, High density lipoprotein

Introduction

Atherosclerosis is a chronic inflammatory disease of the aorta characterized by accumulation of inflammatory cells in the subintimal space [11]. Hyperlipidemia, a major risk factor of atherosclerosis, stimulates the inflammatory process by inducing prolonged retention and modification of lipids in the subintimal space [2]. Blood monocytes recruited by inflam-
matory signals take up modified lipids and differentiate to foam cells, the prominent cell type in atherosclerosis [3]. Although the foam cells mostly originate from recruited monocyte/macrophages, recent studies showed that smooth muscle cells could also take up lipids and differentiate to foam cells [4-7].

These atherosclerotic processes are controlled by two key enzymes that regulate cholesterol metabolism, 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA) reductase and acyl-CoA cholesterol acyltransferase (ACAT) [8,9]. HMG-CoA reductase is the rate-controlling enzyme in cholesterol production. Since inhibition of HMG-CoA reductase can decrease the plasma lipid level, statins such as atorvastatin, simvastatin, rosuvastatin, and lovastatin have been widely used as therapeutic agents for atherosclerosis [9,10]. ACAT is an intracellular enzyme that converts cholesterol to cholesteryl esters (CEs). CEs produced by ACAT1 accumulate in macrophages leading to foam cell formation [11]. ACAT catalyzes cholesterol esterification and plays important roles in lipoprotein assembly, dietary cholesterol absorption, and intracellular cholesterol metabolism [12]. Thus, this enzyme is thought to be responsible for foam cell formation and the subsequent progression of atherosclerosis. Ironically, ACAT deficiency in macrophages exacerbates atherosclerosis in mice due to the toxicity of free cholesterol that accumulates in the cytoplasm [13], whereas partial inhibition of ACAT decreases atherosclerosis without toxicity [11]. Therefore, a compound that can partially inhibit HMG-CoA reductase and/or ACAT might be considered a therapeutic candidate for atherosclerosis.

Previously, polyphenols have been shown to have beneficial effects on atherosclerosis through cholesterol efflux capacity, antioxidative and anti-inflammatory activities [14-16]. 3,4-dihydroxy-hydrocinnamic acid (3,4-DHHCA), a polyphenolic compound, has been reported to have antioxidative and antitumorigenic activities [17,18]. Moreover, in a previous study 3,4-DHHCA reduced plasma lipid levels through inhibition of HMG-CoA reductase in rats fed a high-cholesterol diet, but ACAT was not inhibited by 3,4-DHHCA [19]. Considering its inhibitory effect on HMG-CoA reductase, 3,4-DHHCA may attenuate the formation of atherosclerotic lesions. Nevertheless, the function of 3,4-DHHCA in the pathogenesis of atherosclerosis is yet to be defined. In this study, we show antitherogenic activity of 3,4-DHHCA in rabbits. Interestingly, in this atherosclerosis model, 3,4-DHHCA did not decrease the plasma total cholesterol level but partially inhibited ACAT activity, suggesting its therapeutic potential for the treatment of atherosclerosis.

**Materials and Methods**

1. Animal models and drug administration

New Zealand White (NZW) rabbits aged 3 months and weighing between 2.3 and 2.5 kg were used in these experiments. The rabbits were divided into two groups (n=10 per group), which were provided with a 1% cholesterol diet (RC4, Oriental Yeast Co. Ltd., Tokyo, Japan: controls) or a 1% cholesterol diet containing 0.1% lovastatin or 0.05% 3,4-DHHCA (Sigma, St Louis, MO, USA) for 8 weeks. All rabbits were individually caged and maintained in a controlled facility at 20±2°C, relative humidity of 55±5%, and a strict 12-hr light/dark cycle.

2. Evaluation of atherosclerosis

After blood collection all rabbits were anesthetized with thiopental sodium (Choongwae Pharma Co., Seoul, Korea) and sacrificed by exsanguination from the femoral artery. Immediately after opening the thoracic cavity the aorta was excised and adventitial tissue grossly adhering to the aorta was removed. The aorta was dissected longitudinally and separated into three portions. The first portion, a 1-cm segment proximal to the outlet of the first intercostal artery, was snap-frozen in liquid nitrogen until further processing. The second portion, a segment between the first and the second intercostal artery, was routinely processed, paraffin-embedded and used for histologic examination. The third portion, a segment between the second and the seventh intercostal arteries, was fixed in 10% neutral buffered formalin for 1 day and then placed in absolute propylene glycol for 2 min and stained with oil red-O for 4 hr. After washing, the extent of the oil red O-positive area was measured and expressed as a percentage of the internal
surface using a computer-assisted morphometry system (Image Pro Plus).

3. Immunohistochemistry

The second portion, the paraffin-embedded segment between the first and the second intercostal artery, was cut into 6-μm sections and two serial sections were obtained every 240 mm. To observe the sections by light microscopy, the first section was stained with hematoxylin and eosin. To identify the intimal macrophages, the second serial section was immunostained with commercial mouse antibodies to rabbit macrophages (1:500 dilution; DAKO, Carpinteria, CA, USA) using an avidin/biotin/horseradish peroxidase complex system (Novocastra Laboratories Ltd., Newcastle upon Tyne, UK) in accordance with the manufacturer’s instructions. After immunostaining, the extent of the atherosclerotic lesions in each group was evaluated by a semiquantitative method. A minimum of 20 antibody stained sections for each rabbit were examined and the stage of each lesion was graded from 0 to 3 according to the relative content of intimal macrophage/foam cells (0=normal intima without any subendothelial monocyte/macrophage, 1=isolated monocytes/macrophages in the subendothelial space, 2=single monolayer of monocytes/macrophages underneath the endothelium, 3=presence of multiple layers of monocytes/macrophages as well as transitional and more advanced lesions). The index of the atherosclerotic lesions in each group was obtained from the sum of the stage numbers divided by the number of sections examined.

4. Determination of ACAT activity

ACAT activity was determined using freshly prepared hepatic microsomes according to previously reported protocols [20,21]. Briefly, hepatic microsomes were prepared by ultracentrifugation using Beckman L8-M (Palo Alto, CA) and SW55.1 rotor. 10 μg of the microsomal fraction and 6 μg of cholesterol substrate were preincubated at 37°C for 30 min and the reaction was initiated by adding 20 μL of 5.62 nmol of [14C]-oleoyl-CoA (specific activity=56 mCi/mmol; Life Sciences, MA, USA). Finally, the supernatant was subjected to scintillation counting. The ACAT activity are expressed as picomol of cholesteryl oleate synthesized per min per mg protein.

5. Statistical analysis

Results were expressed as mean±SD. The two-tailed Student’s t-test was used to compare means of different groups and a p-value less than 0.05 was considered to be statistically significant.

Results

1. 3,4-DHHCA did not decrease total plasma cholesterol level in rabbits fed a high-cholesterol diet

The body weights of all rabbits in the control and 3,4-DHHCA groups increased progressively during the experimental period, and there were no significant differences between each group (data not shown). Furthermore, there were no significant lesions in other parenchymal organs of the 3,4-DHHCA group (data not shown). After 8 weeks of a high-cholesterol diet, the plasma total cholesterol levels had dramatically increased in all rabbit groups. The plasma total cholesterol levels of the different groups did not differ significantly during the experimental period (Fig. 1A). The triglyceride (Fig. 1B) and HDL cholesterol (Fig. 1C) levels of the 3,4-DHHCA-supplemented group were also not significantly different from those of the control group.

2. 3,4-DHHCA attenuates atherosclerosis in rabbits fed a high-cholesterol diet

In high-cholesterol diet fed rabbits, the fatty streak lesions of the ascending and descending thoracic aorta in each group were easily identified by staining with oil red O. Broad and fused fatty streak lesions were evident in control rabbits fed the 1% cholesterol diet alone, whereas only sparse well-demarcated, 0.5- to 3-mm-diameter plaques were observed in the 3,4-DHHCA-supplemented groups (Fig. 2A). The percentage area occupied by atherosclerotic lesions on the inner surface between the second and seventh intercostal arteries (the third portion) was significantly lower in the 0.05% 3,4-DHHCA-supplemented group (14.9±6.8%) compared to the control group (63.5±8.2%, p<0.001) (Fig. 2B).
Effects of 3,4-DHHCA on serum lipid levels in rabbits fed a high cholesterol diet for 8 weeks. The serum levels of total cholesterol (A), triglyceride (B) and HDL cholesterol (C) were measured in 3,4-DHHCA-treated and control rabbits fed a high cholesterol diet for 8 weeks.

3. 3,4-DHHCA decreases macrophage content of atherosclerotic lesion in rabbits fed a high-cholesterol diet

Histologically, staining of the second portion, the aortic segment between the first and the second intercostal arteries, with hematoxylin and eosin revealed intimal thickening, mainly due to accumulation of foam cells, infiltration and proliferation of smooth muscle cells in the intima, and deposition of extracellular matrix substances. The intimal thickening was reduced in the 3,4-DHHCA-supplemented groups compared to the control group (Fig. 3A, left panel). By immunohistochemistry using antibody against macrophages, massive accumulation of macrophages was observed in the atherosclerotic intima of the control group, but decreased in the 3,4-DHHCA-treated group (Fig. 3A, right panel). Semiquantitative analysis of the intimal thickening of each group according to subendothelial macrophage content showed significantly lower scores in the 3,4-DHHCA-supplemented group than in the control group ($p<0.001$) (Fig. 3B). These results indicate that 3,4-DHHCA attenuated the accumulation of foamy macrophages in atherosclerotic lesions, suggesting its therapeutic potential.

4. 3,4-DHHCA partially inhibits ACAT activity in rabbits fed a high-cholesterol diet

Although 3,4-DHHCA inhibited HMG-CoA reductase in a previous study [18], total plasma cholesterol levels were not reduced by 3,4-DHHCA in rabbits of our study. However, atherosclerotic lesion formation and macrophage infiltration were significantly decreased by 3,4-DHHCA. These results prompted us to investigate the effect of 3,4-DHHCA on ACAT activity, another important cholesterol metabolizing enzyme. Hepatic ACAT activities were significantly decreased in the 3,4-DHHCA group compared to the control group for rabbits (Fig. 4). In addition, lovastatin, a known HMG-CoA reductase inhibitor, also reduced ACAT activity in rabbits (Fig. 4). Thus, although ACAT activity was not inhibited by 3,4-DHHCA in a rat model, 3,4-DHHCA reduced hepatic ACAT activity in rabbits.
Fig. 3. 3,4-DHHCA reduces atherosclerotic intimal thickening and macrophage accumulation in rabbits fed a high cholesterol diet for 8 weeks. (A) Representative cross-sections of hematoxylin and eosin (H&E) staining (left panel) and immunostaining for macrophage antibody (right panel) on the aortic segment between the first and the second intercostal arteries. Bars represent 95 \( \mu \text{m} \). (B) Quantification of macrophage content in atherosclerotic lesions in the two groups. *Indicates statistical significance (\( p < 0.01 \)).

Fig. 4. Effect of 3,4-DHHCA on hepatic microsomal ACAT enzymatic activities in high cholesterol-fed rabbits. *Significantly different between groups (\( p < 0.05 \)).

Discussion

A previous study demonstrated the lipid lowering activity of 3,4-DHHCA in a rat model. However, the rat model is highly resistant to hyperlipidemia and atherosclerosis and does not develop atherosclerosis, even with a high-cholesterol diet [22]. Therefore, to determine the effect of 3,4-DHHCA on hyperlipidemia and atherosclerosis, we used New Zealand White rabbits in this study.

HMG-CoA reductase is best known for catalyzing a rate-limiting step in cholesterol biosynthesis and its inhibitors are the most effective class of drugs for lowering serum cholesterol concentrations [9]. A previous report showed that 3,4-DHHCA acts as inhibitor of HMG-CoA reductase in a rat model [19]. However, in this study, the serum levels of total cholesterol, triglyceride and HDL cholesterol were not significantly different between 3,4-DHHCA-treated rabbits and controls. Considering the previous report, these results were unexpected. Further study is required to elucidate this difference among animal models.

Based on previous studies showing that ACAT inhibitors prevented atherosclerotic lesion formation in various animal models [23,24], the antiatherosclerotic potential of ACAT inhibitors, such as the drug pactimibe, was investigated in human patients. However, treatment with pactimibe was not effective for the treatment of atherosclerosis in humans [25]. Furthermore, complete deficiency of macrophage ACAT1 exacerbated plaque inflammation, leading to enhanced atherosclerosis, which was attributed to cytotoxicity induced by the increased free cholesterol [13]. Accumulation of free cholesterol induces stress on the endoplasmic reticulum and the formation of cholesterol crystals, leading to inflammation and some activation [26]. Thus, proper control of cytosolic free cholesterol levels is crucial to achieving desirable antiatherosclerotic effects using ACAT inhibitors. Recently, partial inhibition of ACAT was shown to be effective for decreasing the atherosclerotic lesion formation without toxic side effects [27,28]. Therefore, in spite of the failure of clinical trials with ACAT inhibitor, efforts to find new partial ACAT inhibitors with low toxicity should be continued.

Collectively, our data show that 3,4-DHHCA attenuated atherosclerotic lesion formation in rabbits without obvious toxicity and partially inhibited ACAT activity. These results suggest the therapeutic potential of 3,4-DHHCA in the clinical treatment of atherosclerosis.
요 약

폴리페놀 성분은 심혈관질환에서 좋은 효과를 나타내다고 보고되고 있다. 폴리페놀성 화합물인 3,4-다이아이드로록시 하이드로록시나미는 항린에서 나타내는 것을 증명해준다. 

엔자임 A: 콜레스테롤 아킬 트랜스페라제를 억제함으로써 항동맥과는 3,4-다이하이드록시 하이드로시나믹산이 토끼에서 아킬-코에 대조 그룹의 토끼에 비해 22% 감소하였다. 이러한 연구결과에 따라서 3,4-다이하이드록시 하이드로시나믹산을 투여한 토끼에 국부적으로 독성이 관찰되지 않았다. 간의 아킬-코엔자미네인 3,4-다이하이드록시 하이드로시나믹산의 효과에서 전신성이 감소하였고, 병변 내로 침윤한 대식세포의 양도 감소하였다. 토끼에서는 대조 그룹의 토끼에 비해 동맥경화 병변 형성 benchmark 였다. 동맥 부위에서 동맥경화 초기병변이 형성되었다. 반면에 고콜레스테롤 식이를 급여한 대조 그룹 토끼의 광범위한 동맥경화 병변 형성 benchmark 였다. 고콜레스테롤 식이를 급여한 8주 동안 고콜레스테롤 식이를 급여한 대조 그룹 토끼의 토끼에서 동맥경화 병변 형성 benchmark 였다.

요약

고 콜 레 슅� 롬(Cholesterol)은 혈중 콜레스테롤 수치를 높이므로써 동맥경화(arteriosclerosis)에 기여한다. 동맥경화는 동맥의 내막에 지방과 세포의 축적가로, 동맥경화의 진행은 동맥의 내막을 침윤시키고 대식세포의 축적을 일으키며, 동맥경화 병변의 형성을 설명하게 된다. 동맥경화병변은 혈관내피세포의 손상과 대식세포의 증가에 의해 발병한다.

반면에 3,4-다이하이드록시 하이드로시나믹산(3,4-diOH-ca)는 동맥경화 병변 형성을 억제할 수 있는 효과를 보인다. 이는 3,4-다이하이드록시 하이드로시나믹산의 항산화 활성과 항암 활성을 나타낸다고 보고되었다. 폴리페놀성 화합물인 3,4-다이하이드록시 하이드로시나믹산은 항산화 작용을 통해 혈관내피세포의 손상을 예방할 수 있으며, 대식세포의 증가를 억제함으로써 동맥경화 병변의 진행을 억제할 수 있다.

이러한 3,4-다이하이드록시 하이드로시나믹산의 효과는 동맥경화 병변의 진행을 억제하고, 대식세포의 증가를 억제함으로써 동맥경화 병변의 악화를 방지할 수 있다. 따라서 3,4-다이하이드록시 하이드로시나믹산은 동맥경화 예방과 치료에 있어 임상적인 적용을 위한 연구가 필요하다.
yl-coenzyme A:cholesterol acyltransferase: its regulation in vivo and some of its properties in vitro. J Lipid Res. 1980;21: 930-941.

21. Gillies PJ, Rathgeb KA, Perri MA, Robinson CS. Regulation of acyl-CoA:cholesterol acyltransferase activity in normal and atherosclerotic rabbit aortas: role of a cholesterol substrate pool. Exp Mol Pathol. 1986;44:329-339.

22. Russell JC, Proctor SD. Small animal models of cardiovascular disease: tools for the study of the roles of metabolic syndrome, dyslipidemia, and atherosclerosis. Cardiovascular Pathology. 2006;15:318-330.

23. Ikenoya M, Yoshinaka Y, Kobayashi H, Kawamine K, Shibuya K, Sato F. A selective ACAT-1 inhibitor, K-604, suppresses fatty streak lesions in fat-fed hamsters without affecting plasma cholesterol levels. Atherosclerosis. 2007;191:290-297.

24. Tauchi Y, Yoshimi A, Shinbase H, Sato J, Ito K, Morimoto K. Inhibitory effect of acyl-CoA:cholesterol acyltransferase inhibitor-low density lipoprotein complex on experimental atherosclerosis. Biol Pharm Bull. 2003;26:73-78.

25. Nissen SE, Tuzcu EM, Brewer HB, Sipahi I, Nicholls SJ, Ganz P. Effect of ACAT inhibition on the progression of coronary atherosclerosis. N Engl J Med. 2006;354:1253-1263.

26. Duewell P, Kono H, Rayner KJ, Sirois CM, Vladimer G, Bauernfeind FG. NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals. Nature. 2010; 464:1357-1361.

27. Rong JX, Blachford C, Feig JE, Bander I, Mayne J, Kusunoki J. ACAT inhibition reduces the progression of preexisting, advanced atherosclerotic mouse lesions without plaque or systemic toxicity. Arterioscler Thromb Vasc Biol. 2013;33:4-12.

28. Yoshinaka Y, Shibata H, Kobayashi H, Kuriyama H, Shibuya K, Tanabe S. A selective ACAT-1 inhibitor, K-604, stimulates collagen production in cultured smooth muscle cells and alters plaque phenotype in apolipoprotein E-knockout mice. Atherosclerosis. 2010;213:85-91.